



ON TAPE

TV TAKES

NORTH AMERICAN PRECIS SYNDICATE, INC.
350 FIFTH AVENUE • NEW YORK, NY 10118-0110 • (212) 867-9000

HEALTH BULLETIN



SOME CANCER TREATMENT MAY SOON BE GETTING MORE PERSONALIZED. A TYPE OF TREATMENT CALLED ACTIVE IMMUNOTHERAPY MOBILIZES THE BODY'S OWN DEFENSES TO FIGHT DISEASE. RECENT STUDIES INDICATE SUCH THERAPIES MAY BE EFFECTIVE BY ENHANCING THE BODY'S NATURAL THERAPEUTIC REACTION TO CANCER.

EXPERTS SAY THE APPROACH MAY HELP TO DEVELOP A MORE LASTING AND "PERSONALIZED" APPROACH TO FIGHTING CANCER. ACTIVE IMMUNOTHERAPIES TRAIN A PATIENT'S IMMUNE SYSTEM TO RECOGNIZE AND DESTROY TARGET CELLS. IN THIS APPROACH, ONLY CANCER CELLS ARE DESTROYED AND THE EFFECT IS THOUGHT TO BE LONGER LASTING THAN OTHER ALTERNATIVES.

A VACCINE USING THIS APPROACH—BIOVEST'S LEAD THERAPEUTIC VACCINE BIOVAX-I-D—IS CURRENTLY BEING TESTED IN A PHASE THREE TRIAL AT TWENTY-FOUR MEDICAL INSTITUTIONS IN THE U-S FOR TREATMENT OF A TYPE OF NON-HODGKIN'S LYMPHOMA. ONCE ACTIVATED BY THE VACCINE, THE PATIENT'S IMMUNE SYSTEM IS SAID TO HAVE A LONG-LASTING MEMORY OF WHAT THE CANCER CELLS LOOK LIKE AND CAN DESTROY THEM SHOULD THEY RECUR.

TO LEARN MORE, VISIT [WWW--DOT--BIOVEST--DOT--COM](http://WWW.DOT-BIOVEST-DOT-COM).